Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess AZD2014 in Combination With Novel Anti-Cancer Agents in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (INHIBITOR Study)

NCT02780830 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02780830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess AZD2014 in Combination With Novel Anti-Cancer Agents in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (INHIBITOR Study)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2016
Completion date
April 30, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

core: relapsed or refractory diffuse large b-cell lymphoma, module 1: non-gcb diffuse large b-cell lymphoma